Label-free enumeration, collection and downstream cytological and cytogenetic analysis of circulating tumor cells
| Autor: | Elodie Sollier-Christen, Melissa Matsumoto, Edward B. Garon, Kyra Heirich, Corinne Renier, Rosita Montoya, Derek E. Go, Manjima Dhar, Melanie Triboulet, Rajan P. Kulkarni, Rachel Conrad, Dino Di Carlo, Edward Pao, James Che, Nagesh Rao, Stefanie S. Jeffrey, Jianyu Rao, Jonathan H. Goldman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine Pathology medicine.medical_specialty Lung Neoplasms Microfluidics Papanicolaou stain Breast Neoplasms Cell Separation Biology Article 03 medical and health sciences Circulating tumor cell Breast cancer Carcinoma Non-Small-Cell Lung Biomarkers Tumor medicine Carcinoma Humans Anaplastic Lymphoma Kinase In Situ Hybridization Fluorescence Multidisciplinary medicine.diagnostic_test Receptor Protein-Tyrosine Kinases Cancer Neoplastic Cells Circulating medicine.disease 3. Good health 030104 developmental biology Case-Control Studies MCF-7 Cells biology.protein Female Antibody Immunostaining Papanicolaou Test Fluorescence in situ hybridization |
| Zdroj: | Scientific Reports |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/srep35474 |
| Popis: | Circulating tumor cells (CTCs) have a great potential as indicators of metastatic disease that may help physicians improve cancer prognostication, treatment and patient outcomes. Heterogeneous marker expression as well as the complexity of current antibody-based isolation and analysis systems highlights the need for alternative methods. In this work, we use a microfluidic Vortex device that can selectively isolate potential tumor cells from blood independent of cell surface expression. This system was adapted to interface with three protein-marker-free analysis techniques: (i) an in-flow automated image processing system to enumerate cells released, (ii) cytological analysis using Papanicolaou (Pap) staining and (iii) fluorescence in situ hybridization (FISH) targeting the ALK rearrangement. In-flow counting enables a rapid assessment of the cancer-associated large circulating cells in a sample within minutes to determine whether standard downstream assays such as cytological and cytogenetic analyses that are more time consuming and costly are warranted. Using our platform integrated with these workflows, we analyzed 32 non-small cell lung cancer (NSCLC) and 22 breast cancer patient samples, yielding 60 to 100% of the cancer patients with a cell count over the healthy threshold, depending on the detection method used: respectively 77.8% for automated, 60–100% for cytology, and 80% for immunostaining based enumeration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|